Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 26.39% is 88% above its 5-year average of 14.02%, near the high end of its 5-year range (0.97%–34.52%).
3.84% above its 12-month average of 25.41%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
26.39%
RETURN ON EQUITY (ROE) AVG TTM
25.41%
RETURN ON EQUITY (ROE) AVG 3Y
19.99%
RETURN ON EQUITY (ROE) AVG 5Y
14.02%
RETURN ON EQUITY (ROE) AVG 10Y
-16.15%
RETURN ON EQUITY (ROE) AVG 15Y
-23.27%
RETURN ON EQUITY (ROE) AVG 20Y
-35.27%
CURRENT VS TTM AVG
+3.84%
CURRENT VS 3Y AVG
+32.02%
CURRENT VS 5Y AVG
+88.25%
CURRENT VS 10Y AVG
+263.42%
CURRENT VS 15Y AVG
+213.40%
CURRENT VS 20Y AVG
+174.82%
SECTOR MEDIAN · HEALTHCARE
13.38%
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+97.23%
vs the sector median at left
Insulet Corp.
Market Cap
$9.89B
Return on Equity (ROE)
26.39%
TTM Avg
25.41%
3Y Avg
19.99%
5Y Avg
14.02%
Market Cap
$10.03B
Return on Equity (ROE)
12.09%
TTM Avg
11.88%
3Y Avg
12.69%
5Y Avg
13.50%
Market Cap
$9.65B
Return on Equity (ROE)
-57.18%
TTM Avg
-651.33%
3Y Avg
-315.37%
5Y Avg
-198.08%
Market Cap
$9.54B
Return on Equity (ROE)
3.10%
TTM Avg
-8.94%
3Y Avg
-15.72%
5Y Avg
1.14%
Market Cap
$10.38B
Return on Equity (ROE)
-0.17%
TTM Avg
18.91%
3Y Avg
22.60%
5Y Avg
24.60%
Market Cap
$10.46B
Return on Equity (ROE)
20.31%
TTM Avg
18.80%
3Y Avg
15.17%
5Y Avg
15.31%
Market Cap
$11.29B
Return on Equity (ROE)
5.25%
TTM Avg
5.98%
3Y Avg
10.62%
5Y Avg
11.34%
Market Cap
$11.79B
Return on Equity (ROE)
-114.70%
TTM Avg
329.18%
3Y Avg
200.63%
5Y Avg
164.66%
Market Cap
$12.61B
Return on Equity (ROE)
9771.59%
TTM Avg
10.54%
3Y Avg
10.84%
5Y Avg
19.93%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insulet Corp. (PODD) | $9.89B | 26.39% | 25.41% | 19.99% | 14.02% |
| Henry Schein, Inc. (HSIC)vs › | $10.03B | 12.09% | 11.88% | 12.69% | 13.50% |
| Tempus AI, Inc. (TEM)vs › | $9.65B | -57.18% | -651.33% | -315.37% | -198.08% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.54B | 3.10% | -8.94% | -15.72% | 1.14% |
| Molina Healthcare, Inc. (MOH)vs › | $10.38B | -0.17% | 18.91% | 22.60% | 24.60% |
| Universal Health Services, Inc. (UHS)vs › | $10.46B | 20.31% | 18.80% | 15.17% | 15.31% |
| Bio-Techne Corporation (TECH)vs › | $11.29B | 5.25% | 5.98% | 10.62% | 11.34% |
| DaVita Inc. (DVA)vs › | $11.79B | -114.70% | 329.18% | 200.63% | 164.66% |
| Align Technology, Inc. (ALGN)vs › | $12.61B | 9771.59% | 10.54% | 10.84% | 19.93% |
| Oscar Health, Inc. (OSCR)vs › | $7.17B | 26.84% | -21.41% | -36.14% | -25.75% |
ROE
26.4%
ROA
11.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 16.31% |
| 2024-12-31 | 34.52% |
| 2023-12-31 | 28.16% |
| 2022-12-31 | 0.97% |
| 2021-12-31 | 3.02% |
| 2020-12-31 | 1.13% |
| 2019-12-31 | 15.28% |
| 2018-12-31 | 1.55% |
| 2017-12-31 | -16.93% |
| 2016-12-31 | -45.73% |
| 2015-12-31 | -215.91% |
| 2014-12-31 | -61.43% |
| 2013-12-31 | -36.10% |
| 2012-12-31 | -117.41% |
| 2011-12-31 | -80.07% |
| 2010-12-31 | -92.34% |
| 2009-12-31 | -150.48% |
| 2008-12-31 | -2171.06% |
| 2007-12-31 | -58.02% |
| 2006-12-31 | 35.33% |
| 2005-12-31 | 32.74% |
| 2004-12-31 | 31.05% |
| 2003-12-31 | 38.96% |
| 2002-12-31 | 67.44% |
